iBio appoints William D. Clark to board of directors

iBio, Inc.

William D. Clark elected as Class III Director, effective August 23, 2021.
Clark has 30+ years biotech/pharma experience, currently CEO of Genocea Biosciences.
He receives $40k annual cash retainer, additional fees for Audit and Nominating committees, and a 100k-share stock option.
Clark will serve on Audit Committee and Nominating and Corporate Governance Committee.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William D. Clark

Class III Director

IBIO · iBio, Inc.

Effective: 2021-08-23
Filed: August 26, 2021, 7:59 PM ET

On August 23, 2021, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”) elected William D. (Chip) Clark as a Class III Director of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

William D. Clark was elected as Class III Director at iBio, Inc..

Action: elected
Role: Class III Director

Exact text from the filing

On August 23, 2021, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”) elected William D. (Chip) Clark as a Class III Director of the Board.

View on SEC.gov

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-109522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.